CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $244,834 | -39.4% | 5,394 | -45.7% | 0.01% | -62.5% |
| Q4 2022 | $403,858 | -62.0% | 9,935 | -43.3% | 0.02% | -38.5% |
| Q2 2022 | $1,064,000 | -10.1% | 17,513 | -7.1% | 0.04% | -15.2% |
| Q1 2022 | $1,184,000 | +57.7% | 18,861 | +90.3% | 0.05% | +35.3% |
| Q4 2021 | $751,000 | +121.5% | 9,910 | +227.5% | 0.03% | +78.9% |
| Q3 2021 | $339,000 | -56.2% | 3,026 | -36.7% | 0.02% | -62.0% |
| Q2 2021 | $774,000 | -11.0% | 4,780 | -76.7% | 0.05% | -20.6% |
| Q1 2020 | $870,000 | +31.2% | 20,510 | +88.4% | 0.06% | +117.2% |
| Q4 2019 | $663,000 | +47.0% | 10,889 | -1.0% | 0.03% | +26.1% |
| Q3 2019 | $451,000 | – | 11,001 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |